Michael Rosenblatt

In his current role at Flagship, Rosenblatt has helped launch several renowned biotechnology companies in the Flagship ecosystem, including providing counsel on clinical development strategies and chairing or serving on their scientific or clinical advisory committees. He currently serves on the Board of Directors of the Flagship companies Rubius Therapeutics, Cygnal Therapeutics and Ohana Biosciences. He also brings expertise in the development of RNA therapeutics through his current role as a member of Moderna Therapeutics’ Development Committee of the Board and Vaccine Acceleration Committee, and as a consultant to Moderna’s Chief Medical Officer. Rosenblatt most recently served as CMO of Merck from 2009 to 2016.